Trial Profile
Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Phase II Study to Evaluate the Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bimosiamose (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2012 Actual initiation date (25 Feb 2010) added as reported by European Clinical Trials Database.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 21 Sep 2011 Results will be presented at the European Respiratory Society Annual Congress, according to a Revotar Biopharmaceuticals media release.